Montana Chapter of the American College of Cardiology

Latest in Cardiology from ACC.org

• Safety and Efficacy of ProtEmbo Device; TAVR vs. SAVR in Patients with Symptomatic Severe AR at 1 Year
  The ProtEmbo Cerebral Protection System met its primary safety endpoint but failed to meet its primary efficacy endpoint, adding to uncertainty regarding the routine use of cerebral embolic protection (CEP) in TAVR, according to findings from the PROTEMBO IDE trial presented on the final day of TCT 2026.
• EPIC17-VERONICA: Can Platelet Function Testing Guide P2Y12i Deescalation?
  In patients deemed to have very low platelet reactivity, switching from more potent P2Y12 inhibitors to clopidogrel did not improve outcomes at one year, according to findings from the EPIC17-VERONICA trial presented at TCT 2026.
• DUOTAP: Routine Postdilation May Optimize THV Geometry, Hemodynamics
  Routine postdilation with a balloon-expandable transcatheter heart valve (THV) optimized THV geometry and improved hemodynamic performance, without increasing procedure-related adverse events in patients with severe aortic stenosis (AS), according to results from the DUOTAP trial presented at TCT 2026 and simultaneously published in JAMA Cardiology.
• ENCIRCLE: Two-Year Results Following Transeptal TMVR in Patients With Severe MR
  Patients with symptomatic mitral regurgitation (MR) who underwent full percutaneous transseptal transcatheter mitral valve replacement (TMVR) with the SAPIEN M3 system continued to see durable near MR elimination and sustained improvements in functional and health status outcomes at two years...
• IRIS-MAIN: No Statistical Difference in Mortality Between PCI and CABG in Asian Patients With Left Main CAD
  No statistically significant difference in long-term all-cause mortality was observed among Asian patients with unprotected left main coronary artery disease (CAD) who underwent PCI or CABG, based on a non-randomized analysis of the IRIS-MAIN registry presented at TCT 2026 and simultaneously published in The Lancet.